Evidence map›Paper›PMID 40644591›Full record

ArticleClinical nuclear medicine2026

68 Ga-CXCR4-targeted PET/CT Outperforms 18 F-FDG PET/CT in FLT3-mutated AML M1 With Granulocytic Sarcoma : Theranostic Insights.

Özlem Beyler, Halil Kömek, Yunus Güzel, Cengiz Demir, Canan Can

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Özlem BeylerDepartment of Hematology.
Halil KömekDepartment of Nuclear Medicine, Gazi Yaşargil Training and Research Hospital, University of Health Sciences, Diyarbakir, Turkey.
Yunus GüzelDepartment of Nuclear Medicine, Gazi Yaşargil Training and Research Hospital, University of Health Sciences, Diyarbakir, Turkey.ORCID 0000-0002-8555-0460
Cengiz DemirDepartment of Hematology.
Canan CanDepartment of Nuclear Medicine, Gazi Yaşargil Training and Research Hospital, University of Health Sciences, Diyarbakir, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

68 Ga-CXCR4 PET/CT was performed in a patient with acute myeloid leukemia (AML) and granulocytic sarcoma in the left cervical region, who had previously undergone 18 F-FDG PET/CT. Compared with 18 F-FDG PET/CT, 68 Ga-CXCR4 PET/CT revealed a greater number of malignant lymph nodes with more intense uptake in both supradiaphragmatic and infradiaphragmatic regions. Furthermore, markedly increased radiotracer uptake was observed in the bone marrow and spleen compared with FDG. This case underscores the superior sensitivity of 68 Ga-CXCR4 PET/CT in detecting AML infiltration and supports further investigation of CXCR4-targeted imaging and therapeutic approaches in high-risk AML.

Indexed as

Fluorodeoxyglucose F18fms-Like Tyrosine Kinase 3Gallium RadioisotopesLeukemia, Myeloid, AcuteMutationPositron Emission Tomography Computed TomographyPrecision MedicineReceptors, CXCR4Sarcoma, MyeloidTheranostic NanomedicineHumansMaleMiddle AgedCXCR4 protein, humanFLT3 protein, humanFluorodeoxyglucose F18fms-Like Tyrosine Kinase 3Gallium-68Gallium RadioisotopesReceptors, CXCR4acute myeloid leukemiaCXCR4FDGgranulocytic sarcomaPET/CT

Identifiers

PMID40644591
PMCPMC13132033

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.